Loading…
No business profile yet.
Size Foresee Pharmaceuticals (6576.TWO) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $343M, the 602nd largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$71.90 on 6 Nov 2026.
Performance Over six months the shares fell 9.4%, against -20.8% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 5th highest of 19 in its peer set.
Growth Revenue grew 6.4% over the last twelve months (peer median -5.7%); the operating margin is -104.5% (peer median -17.1%).
Valuation It trades at 22.9× enterprise value to sales against a peer median of 4.9× (4th most expensive of 18).
Capital Return on invested capital runs 56.8 points below its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$471M | NT$431M | NT$419M | NT$195M | NT$302M |
| Revenue growth | — | +3% | +115% | -35% | — |
| Gross profit | NT$317M | NT$236M | NT$169M | NT$50.1M | NT$235M |
| EBITDA | -NT$436M | -NT$794M | -NT$999M | -NT$934M | -NT$418M |
| Net income | NT$22.5M | -NT$883M | -NT$1.08B | -NT$1.04B | -NT$473M |
| Free cash flow | -NT$593M | -NT$845M | -NT$1.32B | -NT$934M | -NT$589M |
| Capital expenditure | NT$54.7M | NT$15.5M | NT$156M | NT$46.3M | NT$58.1M |
| Total debt | NT$398M | NT$232M | NT$260M | NT$228M | NT$41.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6576.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.4% | -10.4% | 9th highest of 19 |
| 6-month return | -9.4% | -20.8% | 5th highest of 19 |
| Distance from 52-week high | -23.3% | -33.5% | 5th highest of 20 |
| Revenue growth (TTM) | +6.4% | -5.7% | 7th highest of 19 |
| Operating margin | -104.5% | -17.1% | 5th lowest of 18 |
| EV / Sales | 22.9× | 4.9× | 4th most expensive of 18 |
| ROIC minus cost of capital | -56.8 pp | -11.4 pp | 2nd lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Foresee Pharmaceuticals 6576.TWO | Taiwan | $343M | -9% | +6% | -104% | 22.9× | n/a | n/a |
| BioDlink International 1875.HK | Hong Kong | $342M | -29% | -51% | -31% | 4.9× | n/a | n/a |
| ASKA Pharmaceutical 4886.T | Japan | $342M | -31% | +11% | n/a | n/a | n/a | n/a |
| Autolus Therapeutics Plc Sponsored ADR AUTL | United States | $341M | -18% | +288% | -211% | 4.3× | n/a | n/a |
| Atea Pharmaceuticals AVIR | United States | $346M | -21% | n/a | n/a | n/a | n/a | n/a |
| Opus Genetics IRD | United States | $348M | -19% | -36% | -513% | 29.9× | n/a | n/a |
| Zhejiang East Asia Pharmaceutical 605177.SS | China | $348M | -3% | +3% | -17% | 3.1× | n/a | n/a |
| Pharmicell 005690.KS | South Korea | $352M | -56% | +51% | 32% | 3.2× | -6.6% | +24.8% |
| Chengdu Huasun Technology 000790.SZ | China | $333M | -22% | -36% | -57% | 5.9× | 28.5% | -6.4% |
| Honz Pharmaceutical 300086.SZ | China | $330M | -35% | -23% | -54% | 7.9× | 58.0% | -12.8% |
| Lumosa Therapeutics 6535.TWO | Taiwan | $356M | -49% | -8% | -883% | 324.5× | n/a | n/a |
| Standard Chemical & Pharmaceutical 1720.TW | Taiwan | $329M | 0% | +3% | 21% | 1.8× | -10.4% | +10.3% |
| Beihai Gofar Chuanshan Biological 600538.SS | China | $328M | -38% | +10% | -8% | 6.2× | n/a | n/a |
| Hangzhou Tianmushan Pharmaceutical Enterprise 600671.SS | China | $327M | -10% | -19% | 5% | 11.5× | 22.5% | +0.5% |
| Enwei Pharmaceutical 301331.SZ | China | $326M | -20% | -7% | 5% | 2.3× | 15.1% | +7.3% |
| KYORIN Pharmaceutical 4569.T | Japan | $362M | -30% | -5% | 2% | 0.5× | 10.5% | +4.2% |
| Solara Active Pharma Sciences SOLARA.NS | India | $323M | +23% | +27% | 8% | 2.3× | 37.7% | -3.2% |
| TRex Bio TRXB | United States | $364M | n/a | -100% | n/a | n/a | n/a | n/a |
| Hainan Huluwa Pharmaceutical 605199.SS | China | $322M | -21% | -32% | -58% | 5.0× | 2.5% | -4.9% |
| 6467 6467.TW | Taiwan | $322M | n/a | n/a | -2,618% | 1,229.5× | n/a | n/a |
| Ind-Swift Laboratories INDSWFTLAB.NS | India | $321M | +149% | +66% | 9% | 3.5× | n/a | n/a |